Clinical trial
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
NCT00209092 · Emory University, Other · Completed
Key facts
| NCT number | NCT00209092 |
|---|---|
| Title | Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer |
| Official title | Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer |
| Lead sponsor | Emory University, Other |
| Collaborators | Georgia Center for Oncology Research & Education Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine |
| Enrollment | 51 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Oct 1, 2012 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 27, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: